Bergisch Gladbach, Germany 8/14/14—Miltenyi Biotech, a provider of products and services for biomedical research and cellular therapy, has acquired Lentigen’s lentiviral-vector–manufacturing business and related assets, including intellectual property and process technologies. The purchase price was not disclosed. “It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale,” stated Miltenyi CEO Stefan Miltenyi. “With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner.” The acquired operations will become a US subsidiary, Lentigen Technology. Miltenyi has granted certain rights to deploy the technology in some therapeutic indications to the sellers, now operating as Opus Bio.